Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Sorrento Therapeutics Inc. (SRNE)

7.32   0.04 (0.55%) 05-06 08:09
Open: 7.3151 Pre. Close: 7.28
High: 7.6299 Low: 7.255
Volume: 5,212,368 Market Cap: 2,091M
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.648 - 7.698 7.698 - 7.744
Low: 7.138 - 7.201 7.201 - 7.258
Close: 7.223 - 7.322 7.322 - 7.411

Technical analysis

as of: 2021-05-05 5:37:43 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 9.57     One year: 10.59
Support: Support1: 6.78    Support2: 5.64
Resistance: Resistance1: 8.20    Resistance2: 9.07
Pivot: 7.86
Moving Average: MA(5): 7.84     MA(20): 7.72
MA(100): 9.42     MA(250): 8.43
MACD: MACD(12,26): -0.23     Signal(9): -0.27
Stochastic oscillator: %K(14,3): 24.63     %D(3): 43.14
RSI: RSI(14): 39.51
52-week: High: 19.39  Low: 2.52  Change(%): 203.7
Average Vol(K): 3-Month: 1038920  10-Days: 743373

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
SRNE has closed above bottom band by 22.4%. Bollinger Bands are 49.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to SRNE's normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Thu, 06 May 2021
Analysts Anticipate Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Will Announce Quarterly Sales of $17.25 Million - MarketBeat

Wed, 05 May 2021
Moving Average Crossover Alert: Sorrento Therapeutics (SRNE) - Yahoo Finance

Mon, 03 May 2021
Sorrento Therapeutics (SRNE) Stock Surges 20% from the recent low: A Bullish Sign? – Own Snap - Own Snap

Tue, 27 Apr 2021
Sorrento Therapeutics Inc (SRNE) Stock Suddenly Jumps On FDA Clearance with Phase 2 study for Sti-3031 – Own Snap - Own Snap

Mon, 26 Apr 2021
Sorrento Therapeutics Inc (SRNE) Stock Comes Back Strongly: What's The Buzz? – Own Snap - Own Snap

Wed, 14 Apr 2021
Is Sorrento Therapeutics Inc (SRNE) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Outperform
Return on Equity: Neutral Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 286
Shares Float (M) 243
% Held by Insiders 11.22
% Held by Institutions 28.24
Shares Short (K) 59,550
Shares Short P. Month (K) 56,070

Stock Financials

EPS -1.300
EPS Est This Year -1.070
EPS Est Next Year -0.650
Book Value (p.s.) 0.620
Profit Margin
Operating Margin -503.99
Return on Assets (ttm) -23.0
Return on Equity (ttm) -362.5
Qtrly Rev. Growth -11.7
Gross Profit (p.s.) -0.285
Sales Per Share 0.140
EBITDA (p.s.) -0.667
Qtrly Earnings Growth
Operating Cash Flow (M) -160
Levered Free Cash Flow (M) -127

Stock Valuations

PE Ratio -5.63
PEG Ratio
Price to Book value 11.81
Price to Sales 52.29
Price to Cash Flow -13.11

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.